Skip to main content
. Author manuscript; available in PMC: 2009 Nov 15.
Published in final edited form as: Cancer Res. 2008 Nov 15;68(22):9358–9366. doi: 10.1158/0008-5472.CAN-08-1860

Table 1.

Alteration of RKO cell cycle response to decitabine (DAC) following p53R2 knockdown

Treatment1 % of cells
G1 S G2
PBS, control siRNA2 39.5 ± 0.9 40.3 ± 1.0 20.2 ± 0.3
PBS, p53R2 siRNA 36.1 ± 1.7 40.9 ± 4.9 23.0 ± 3.2
0.5 μM DAC, control siRNA 52.6 ± 1.2 27.3 ± 0.3 20.1 ± 1.0
0.5 μM DAC, p53R2 siRNA 43.4 ± 0.9 31.2 ± 1.4 25.4 ± 0.5
2.0 μM DAC, control siRNA 57.2 ± 1.1 17.9 ± 0.6 24.9 ± 1.2
2.0 μM DAC, p53R2 siRNA 46.0 ± 1.7 22.3 ± 1.2 31.7 ± 0.9
1

Cells were treated with siRNA for 24 hours, and then treated with DAC. Three days later, cells were harvested for flow cytometry analysis as described in the Materials and Methods.

2

All siRNA treatments (control and p53R2 siRNA) utilized 50nM concentrations of siRNA.